Klinikum Klagenfurt am Wörthersee
Klagenfurt 9020
1 studies enrolling now · 11 studies all time
What they study most
Alpha1-Antitrypsin Deficiency, Carcinoma, Hepatocellular, Esophageal Squamous Cell Carcinoma, Fistulizing Crohn's Disease, Gastroparesis, Geographic Atrophy, Heart Failure, Limited-Stage Small Cell Lung Cancer, Migraine, Non Alcoholic Steatohepatitis (NASH), Ulcerative Colitis
Studies at this site
- Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein — Recruiting now
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy — Running, not enrolling
- Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications — Completed
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) — Running, not enrolling
- A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer — Running, not enrolling
- A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma — Completed
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis — Completed
- Benefits of Microcor in Ambulatory Decompensated Heart Failure — Completed
- Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
- Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease — Completed
- Diabetic Gastroparesis Study 05 — Stopped early